| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bae1a68f7fc60fe5e6aa97c910ed37dc |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12R2001-225
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2400-169
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12R2001-25
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2002-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-747
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23C19-0323
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23C9-1234
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N1-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N1-205
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23C15-123 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-25
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-225 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-747
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23L1-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-20 |
| filingDate |
2007-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_53e92cf38c2b0e831f22c63118b6a967
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_85a5aed9bf70f0d0a3f0cadd31e2d05f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9cc1066ff4729ee7ea99b2a2b47e1714
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_16d7c7a249906bd09b1ed6561aa4ecfa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b3b94d9e3cd5ae63f5acfa86be2ce7d0 |
| publicationDate |
2009-09-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-2101596-A1 |
| titleOfInvention |
Immunomodulating probiotic lactic acid bacteria |
| abstract |
The present invention relates to immuno modulat ing probiotic lactic acid bacteria, to methods wherein the bacteria are used to reduce allergy, and to food products wherein the bacteria may be in incorporated to reduce allergy upon consumption of the product. Preferred probiotic lactic acid bacteria stimulate the Th1 and/or Th3 responses and/or represses Th2 responses as may be determined by the cytokine profiles that are induced in human peripheral blood mononuclear cells upon coincubation with the lactic acid bacteria. |
| priorityDate |
2006-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |